Today’s Research Reports on Stocks to Watch: Innovate Biopharmaceuticals and Clearside BioMedical
NEW YORK, NY / ACCESSWIRE / March 6, 2018 / Shares of both Innovate Biopharmaceuticals and Clearside BioMedical were heating up the biotech arena in the market on Monday. Innovate has now seen big gains on two trading days in a row on scarce news. Clearside released positive data regarding the efficacy and safety of suprachoroidal CLS-TA.
RDI Initiates Coverage on:
Innovate Biopharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=INNT
Clearside BioMedical, Inc.
https://rdinvesting.com/news/?ticker=CLSD
Innovate Biopharmaceuticals, Inc. shares were on fire in Monday trading, closing the day up 82.49% on about 4.4 million shares traded. The stock saw explosive moves despite no remarkable news released by the company. Trading volume at 4.4 million shares was also significantly higher compared to the stock's average of about 53,000 shares. This past Friday the stock had also seen gains of over 50% despite any news. It was recently that the company completed a reverse capitalization with Monster Digital. The company has a lead product candidate called larazotide (INN-202) that is intended for the treatment of celiac disease.
Access RDI’s Innovate Biopharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=INNT
Clearside BioMedical, Inc. shares exploded on Monday to close up 32.10% on about 14.5 million shares traded. The stock zoomed to a new high of $13.25 during intra-day trading after the biopharma company announced at the end of last week that it was expecting to release data regarding one of its lead development assets yesterday. The release was out and it was related to a phase 3 trial called PEACHTREE that investigates the safety and efficacy of suprachoroidal CLS-TA in patients that have macular edema associated with non-infectious uveitis. The trial hit on both primary and secondary endpoints and CEO Daniel White said in a statement accompanying the release, "We currently expect to submit a new drug application for suprachoroidal CLS-TA in patients with macular edema associated with uveitis to the FDA in the fourth quarter of 2018, and we are also evaluating a number of options for submissions to regulatory agencies in additional territories outside of the United States"
Access RDI’s Clearside BioMedical, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CLSD
Our Actionable Research on Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) and Clearside BioMedical, Inc. (NASDAQ: CLSD) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
